OBESITY – AN ELEMENT OF METABOLIC SYNDROME
Corresponding author:
[email protected]
Accepted
28 March 2026
Available Online
15 June 2018
Abstract
METABOLIC SYNDROME (MS) IS DEFINED BY LOW TOLERANCE TO GLUCOSE, DYSLIPIDEMIA, HYPERTENSION, OBESITY AND HYPERINSULINEMIA. THROUGH ALL OF THESE FACTORS MS FAV ORS INCREASED CARDIOVASCULAR RISK, WHICH IS WHY IT SHOULD BE DETECTED EARLY. ALTHOUGH THESE FACTORS IN THE MS HAVE BEEN KNOWN FOR SOME TIME, THE MOST IMPORTANT IS INSULIN RESISTANCE. DUE TO INSULIN RESISTANCE, PEOPLE WITH MS HAVE A HIGH RISK OF MORTALITY D UE TO CORONARY ARTERY DISEASE. THE CONCEPT OF MS IS AN OPEN WINDOW TO RESEARCH, A CONCEPT OPEN TO THE NEW, AN IMPORTANT TOPIC OF DEBATE IN TERMS OF ITS SPREADING AREA AND THE EVER-INCREASING GLOBAL INCIDENCE. THE FIRST EPIDEMIOLOGICAL STUDY OF THE PREVALEN CE OF OBESITY AND RISK FACTORS FOR OBESITY IN THE ADULT POPULATION IN ROMANIA WAS PUBLISHED IN 2015 AND ESTIMATED THAT 21.3% OF ROMANIANS AGED OVER 18 YEARS SUFFER FROM OBESITY. THE TOPIC ADDRESSED IN THIS PAPER BELONGS TO A PRIORITY AREA OF PUBLIC HEALTH IN THE EUROPEAN UNION AND ROMANIA. THE MAIN PURPOSE OF THIS WORK WAS TO ANALYZE THE ASSOCIATION OF OBESITY WITH OTHER CHRONIC CONDITIONS SUCH AS: T2DM, HYPERTENSION, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, DYSLIPIDEMIA, LIVER STEATOSIS, BILIARY LITHIASIS.
Keywords
HYPERTENSION
METABOLIC SYNDROME
DYSLIPIDEMIA
OBESITY
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Adiels M, Olofsson SO, Taskinen MR, Boren J . Overproduction of very low -density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225-1236
[2]
Hoenig MR. Implications of the obesity epidemic for lipid -lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vascular Health and Risk Management 2008:4(I) 143-156.
[3]
Kenneth R Feingold, Carl Grunfeld. Obesity and dislipidemia. NCBI, 2015.
[4]
Bays, H.E., et al., Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol, 2013. 7(4): p. 304-83.
[5]
Colditz GA, Willett WC, Rotnitzky A et al . Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481–486.
[6]
Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health. 2005;59(2):134–139.
[7]
Look AHEAD Research Group. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one -year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383.
[8]
Steinberg H.D., Tarshoby M., Menestel R. et al . Elevated circulating free fatty acid levels impair endothelium –dependent vasodilatation. J Clin Invest, 1997, 100, 1230-1239
[9]
Davda R.K., Stepniakowski K.T., Ullian M.E . et al. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C independent mechanism. Hypertension, 1995, 26, 764-770.
[10]
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH . The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–1529.
[11]
Klein S, Burke LE, Bray GA, et al. American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004;110(18):2952– 2967.
[12]
Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB . Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–1872.
[13]
Fox CS, Pencina MJ, Wilson PW et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31(8):1582– 1584.
[14]
Dorobanţu Maria, Bădilă Elisabeta, Darabont Roxana et al. Studiul SEPHAR -studiu de prevalenţă a hipertensiunii arteriale şi evaluare a riscului cardiovascular în România. Revista Română de Cardiologie, vol.XXI, Nr.3, 2006.
[15]
Wajchenberg BL, Gianella -Netto D, Da Silva MER et al. Depot - specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to metabolic syndrome. Horm Metab Res 2002; 34:612-621.
[16]
Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006;20:981-96.
[17]
Stampfer MJ, Maclure KM , Colditz GA, et al. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr 1992; 55: 652–658.
[18]
Tsai C-J, Leitzmann MF, Willett WC et al. Central Adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut 2006; 55: 708-714.